DENİZ LENGERLİ
ASST. PROF.



Email : deniz.lengerli@gazi.edu.tr
Office Phone : +90 312 202 3226
International Researcher IDs
ScholarID: SC5VVRMAAAAJ
ORCID: 0000-0001-9838-8995
Publons / Web Of Science ResearcherID: AHA-9329-2022
ScopusID: 57217036994
Yoksis Researcher ID: 329342

Learning Knowledge

Doctorate 2016 - 2021	Gazi University, Sağlık Bilimleri Enstitüsü, Turkey
Undergraduate 2010 - 2015	Gazi University, Eczacılık Fakültesi, Turkey

Dissertations

Doctorate, STUDIES ON THE SYNTHESIS AND ANTICANCER ACTIVITY OF NOVEL 2,4-DIAMINOPYRIMIDINE DERIVATIVES, Gazi University, Sağlık Bilimleri Enstitüsü, 2021

Academic Titles / Tasks

Lecturer 2020 - Continues	Gazi University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri

Supported Projects

1. Banoğlu E., Çalışkan B., TUBITAK Project, Meme ve Karaciğer Kanserinin Tedavisi için PI3K/Akt Sinyal Yolunu Hedefleyen Yeni Aday İlaç Molekül Geliştirme ve Ön klinik Çalışmaları, 2016 - 2019

Awards

1. Banoğlu E., Lengerli D., TÜBA-TEKNOFEST DOKTORA TEZ ÖDÜLÜ, Tüba, September 2022

Published journal articles indexed by SCI, SSCI, and AHCI

1. **Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification**
   Saatci O., Akbulut O., Cetin M., Sikirzhytski V., ÜNER M., LENGERLİ D., O'Quinn E. C., Romeo M. J., ÇALIŞKAN B.,

BANOĞLU E., et al.
Cell Death and Differentiation, vol.30, no.5, pp.1305-1319, 2023 (SCI-Expanded)

2. **The 1,2,3-triazole 'all-in-one' ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool.**
Lengerli D., Ibis K., Nural Y., Banoglu E.
Expert opinion on drug discovery, vol.17, no.11, pp.1209-1236, 2022 (SCI-Expanded)
3. **Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with in Vitro Growth Inhibitory and in Vivo Antitumor Activity**
Turanll S., NALBAT E., LENGERLİ D., İBİŞ K., Güntekin Ergün S., Akhan Güzelcan E., MUYAN M., Cetin-Atalay R., Çallşkan B., BANOĞLU E.
ACS Omega, vol.7, no.41, pp.36206-36226, 2022 (SCI-Expanded)
4. **A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate**
Akbulut O., Lengerli D., Saatci O., Duman E., ŞEKER U. Ö. Ş., Isik A., AKYOL A., ÇALIŞKAN B., BANOĞLU E., ŞAHİN Ö.
MOLECULAR CANCER THERAPEUTICS, vol.19, no.6, pp.1243-1254, 2020 (SCI-Expanded)

Articles Published in Other Journals

1. **Crystal structure and Hirshfeld surface analysis 4-(4-chlorophenyl)-5-methyl-3-{4-[(2-methylphenyl)methoxy]pnenyl}-1,2-oxazole**
Aydin A., AKKURT M., TURANLİ S., LENGERLİ D., BANOĞLU E., Ozcelik N. D.
ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, vol.77, pp.346-356, 2021 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

1. **A NOVEL SERIES OF ANTIPYRINE-UREA ANALOGUES: DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE**
LENGERLİ D.
International Multidisciplinary Symposium on Drug Research and Development (DRD) 2023, 4 - 06 May 2023
2. **STUDIES ON THE SYNTHESIS AND ANTICANCER POTENTIAL OF NOVEL 2,4-DIAMINOPYRIMIDINE DERIVATIVES**
Lengerli D., Akbulut Çalışkan Ö., Çalışkan B., Şahin Ö., Banoğlu E.
The 9th Young Medicinal Chemist Symposium (EFMC-YMCS 2022), Nice, France, 8 - 09 September 2022
3. **DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL IMIDAZOLIDINONE-THIAZOLE AMIDE HYBRIDS AS INHIBITORS OF HUMAN SOLUBLE EPOXIDE HYDROLASE**
İbiş K., Lengerli D., Jordan P. M., Çalışkan B., Werz O., Banoğlu E.
9th EFMC Young Medicinal Chemists' Symposium, Nice, France, 8 - 09 September 2022
4. **TACC3 İnhibitörü Yeni 2,4-Diaminopirimidin Türevlerinin Sentezi, Anti-Kanser Etki Potansiyelleri ve İlaç Benzeri Özelliklerinin Değerlendirilmesi Üzerine Çalışmalar**
LENGERLİ D., AKBULUT ÇALIŞKAN Ö., ÇALIŞKAN B., ŞAHİN Ö., BANOĞLU E.
VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Turkey, 26 August 2022
5. **Synthesis of 3,4-Diaryl-5-methylisoxazoles with Potent Antiproliferative Activity Against a Panel of Human Liver and Breast Cancer Cell Lines**
LENGERLİ D., TURANLİ S., ÇALIŞKAN B., AKHAN GÜZELCAN E., NALBAT E., ATALAY R., BANOĞLU E.
EFMC-ISMC EFMC-YMCS Virtual Poster Session, 09 September 2020
6. **Synthesis of New Vicinal Diaryl Five-Membered Heterocyclic Compounds with Potential Anticancer Activity**
TURANLİ S., LENGERLİ D., ÇALIŞKAN B., AKHAN GÜZELCAN E., NALBAT E., ATALAY R., BANOĞLU E.
8th International Drug Chemistry Conference, 27 February - 01 March 2020
7. **A SMALL MOLECULE INHIBITOR OF TRANSFORMING ACIDICCOILED-COIL PROTEIN 3 (TACC3): A**

NOVEL THERAPEUTICSTRATEGY FOR THE TREATMENT OF BREAST CANCER
LENGERLİ D., Akbulut O., ÇALIŞKAN B., ŞAHİN Ö., BANOĞLU E.
11th Joint Meeting on Medicinal Chemistry 2019, PRAG, Czech Republic, 27 - 30 June 2019

8. **Abstract 3871: A novel TACC3 inhibitor as an anti-cancer agent in breast cancer**
Akbulut O., LENGERLİ D., Saatci O., Duman E., Seker U., ÇALIŞKAN B., BANOĞLU E., ŞAHİN Ö.
Experimental and Molecular Therapeutics, 29 March - 03 April 2019
9. **A Novel TACC3 inhibitor as an anti-cancer agent in breast cancer**
AKBULUT ÇALIŞKAN Ö., LENGERLİ D., ÇALIŞKAN B., BANOĞLU E., ŞAHİN Ö.
30th EORTC-NCI-AACR Symposium, Dublin, Ireland, 13 - 16 November 2018

Patent

Banoğlu E., Çalışkan B., Muyan M., Atalay R., Erson Bensan A. E., Lengerli D., Güntekin S., Turanlı S., İbiş K., ANTİKANSER AKTİVİTEYE SAHİP YENİ VİSİNAL DİARİL HETEROSİKLİK BİLEŞİK TÜREVLERİ, Patent, CHAPTER A Human Needs, The Invention Registration Number: TR 2019 14610 B , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Lim C., Cruz E., Vempati S., TW111113780-COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 111113780 , Standard Registration, 2022

Banoğlu E., Çalışkan B., İbiş K., Lengerli D., Şahin Ö., Akbulut Ö., Lim C., Cruz E., Vempati S., JP2022-527677-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 2022-527677 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Vempati S., Lim C., Cruz E., KR10-2022-7020047-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: KR10-2022-7020047 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Vempati S., Lim C., Cruz E., CN 202080091759.9 (2022110200431050)-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: CN 115279754 A (2022072000921700) , Standard Registration, 2022

Banoğlu E., Çalışkan B., İbiş K., Lengerli D., Şahin Ö., Akbulut Ö., Lim C., Cruz E., Vempati S., EP20888312.4-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: EP/20888312.4 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Vempati S., Lim C., Cruz E., PCT/US2022/024263 (WO2022/221194 A1) COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US22/24263 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Lim C., Vempati S., Cruz E., US17/776,767-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US17/776,767 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., Şahin Ö., Akbulut Ö., HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-HongKong, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 62021037626.0 , 2021

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Lim C., Cruz E., Vempati S., COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US63173796 , 2021

Banoğlu E., Çalışkan B., Lengerli D., Şahin Ö., Akbulut Ö., HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-CN, Patent, CHAPTER A Human Needs, The Invention Recourse Number: CN201980049280.6 , 2021

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Lim C., Vempati S., Cruz E., ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS (US/PCT), Patent, CHAPTER A Human Needs, The Invention Recourse Number: PCT/US/2020/060588 , 2020

Banoğlu E., Çalışkan B., Şahin Ö., Lengerli D., Akbulut Ö., ANTİ-KANSER AJANI OLARAK KULLANILABİLECEK YENİ POTANSİYEL TACC3 İNHİBİTÖRÜ (BRP-OZG-264), Patent, CHAPTER A Human Needs, The Invention Registration Number: 2018 07464 , Standard Registration, 2020

Banoğlu E., Çalışkan B., Lengerli D., Şahin Ö., Akbulut Ö., HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER

DRUG CANDIDATE-JP, Patent, CHAPTER A Human Needs, The Invention Recourse Number: JP2021-516520 , 2020
Banoğlu E., Çalışkan B., Şahin Ö., Lengerli D., Akbulut Ö., HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-US, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US17/058.982 , 2020
Banoğlu E., Çalışkan B., Lengerli D., Şahin Ö., Akbulut Ö., HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-KR, Patent, CHAPTER A Human Needs, The Invention Recourse Number: KR10-2020-7037075 , 2020
Banoğlu E., Çalışkan B., Lengerli D., Şahin Ö., Akbulut Ö., HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-EP, Patent, CHAPTER A Human Needs, The Invention Recourse Number: EP19837587.5 , 2020
Banoğlu E., Çalışkan B., Şahin Ö., Lengerli D., Akbulut Ö., ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: EP19209120.5 , Standard Registration, 2019

Metrics

Publication: 14
Citation (WoS): 31
Citation (Scopus): 33
H-Index (WoS): 3
H-Index (Scopus): 3

Congress and Symposium Activities

8th International BAU Drug Design Congress, Audience, İstanbul, Turkey, 2022
9th EFMC Young Medicinal Chemists' Symposium, Attendee, Nice, France, 2022
VI. Ulusal Farmasötik Kimya Kongresi, Attendee, İstanbul, Turkey, 2022
8th International Drug Chemistry Conference, Attendee, Antalya, Turkey, 2020

Research Areas

Health Sciences, Pharmacology and Therapeutics, Professional Sciences, Pharmaceutical Chemistry